Integrated biomarker landscape for the early detection and management of calcific aortic valve disease

Background: Calcific aortic valve disease (CAVD) is the predominant valvular pathology in older adults, advancing from aortic sclerosis to life-threatening stenosis. Without effective medical therapies, intervention mainly relies on timely valve replacement, although silent myocardial and valvular d...

Descripción completa

Detalles Bibliográficos
Autores: Cook-Calvete, Alberto, Moreta, Silvia, Delgado-Marin, Maria, Fernandez-Rodriguez, Blanca, Zaragoza, Carlos, Saura, Marta
Tipo de recurso: artículo
Fecha de publicación:2026
País:España
Institución:Universidad de Málaga
Repositorio:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
Idioma:inglés
OAI Identifier:oai:ddfv.ufv.es:10641/6717
Acceso en línea:https://hdl.handle.net/10641/6717
Access Level:acceso abierto
Palabra clave:aging
biomarkers
calcific aortic valve disease
cardiovascular disease
Calcific aortic valve disease
Aging
Biomarkers
Cardiovascular disease
General Medicine
Biochemistry
Clinical Biochemistry
SDG 3 - Good Health and Well-being
Journal Article
Review
yes
id ES_862ca3f9010b8e1ec7dbcb03dd7bef63
oai_identifier_str oai:ddfv.ufv.es:10641/6717
network_acronym_str ES
network_name_str España
repository_id_str
spelling Integrated biomarker landscape for the early detection and management of calcific aortic valve diseaseCook-Calvete, AlbertoMoreta, SilviaDelgado-Marin, MariaFernandez-Rodriguez, BlancaZaragoza, CarlosSaura, Martaagingbiomarkerscalcific aortic valve diseasecardiovascular diseaseCalcific aortic valve diseaseAgingBiomarkersCardiovascular diseaseGeneral MedicineBiochemistryClinical BiochemistrySDG 3 - Good Health and Well-beingJournal ArticleReviewyesBackground: Calcific aortic valve disease (CAVD) is the predominant valvular pathology in older adults, advancing from aortic sclerosis to life-threatening stenosis. Without effective medical therapies, intervention mainly relies on timely valve replacement, although silent myocardial and valvular damage may progress before symptoms arise. Early, non-invasive detection of disease activity is a crucial unmet need. Aims: To review circulating and mechanistic biomarkers reflecting the core pathogenic pathways of CAVD and asses their potential for early detection and patient-specific risk stratification. Methods: Narrative review of literature focusing on traditional protein biomarkers, emerging non-coding RNAs, and extracellular vesicles (EVs) associated with lipid oxidation and inflammation, bone and mineral metabolism, extracellular matrix (ECM) remodelling, endothelial dysfunction and non-coding RNA regulation. Results: Traditional protein biomarkers—such as lipoprotein(a), osteopontin, fetuin-A, galectin-3 and matrix metalloproteinases—offer insights into the disease and correlate with disease burden but lack sensitivity for detecting early-stage CAVD. Emerging non-coding RNA markers, including long non-coding RNAs (lncRNAs) and microRNAs (like miR-30b and miR-125b), show promise as predictive and diagnostic tools by mediating key molecular pathways involved in calcification and inflammation. EVs, which carry proteins, lipids and nucleic acids across all pathogenic pathways, provide stable and comprehensive signatures that enhance risk stratification compared to conventional markers. Notably, no single biomarker has demonstrated sufficient sensitivity or specificity across all stages of the disease. Combining proteins, RNAs and EV cargo into integrative, multimodal panels—supported by proteomics and transcriptomics—provides the greatest potential for early detection and patient-specific management. However, further validation in prospective cohorts and standardization of assays are necessary before clinical implementation. Conclusion: Biomarker-guided approaches could revolutionize CAVD management by enabling early detection and patient stratification before irreversible valvular damage occurs.Facultad de Medicina20262026-01-0120262026-01-01review articlehttp://purl.org/coar/resource_type/c_dcae04bcinfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10641/6717reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoriainstname:Universidad de MálagaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddfv.ufv.es:10641/67172026-06-11T12:44:57Z
dc.title.none.fl_str_mv Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
title Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
spellingShingle Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
Cook-Calvete, Alberto
aging
biomarkers
calcific aortic valve disease
cardiovascular disease
Calcific aortic valve disease
Aging
Biomarkers
Cardiovascular disease
General Medicine
Biochemistry
Clinical Biochemistry
SDG 3 - Good Health and Well-being
Journal Article
Review
yes
title_short Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
title_full Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
title_fullStr Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
title_full_unstemmed Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
title_sort Integrated biomarker landscape for the early detection and management of calcific aortic valve disease
dc.creator.none.fl_str_mv Cook-Calvete, Alberto
Moreta, Silvia
Delgado-Marin, Maria
Fernandez-Rodriguez, Blanca
Zaragoza, Carlos
Saura, Marta
author Cook-Calvete, Alberto
author_facet Cook-Calvete, Alberto
Moreta, Silvia
Delgado-Marin, Maria
Fernandez-Rodriguez, Blanca
Zaragoza, Carlos
Saura, Marta
author_role author
author2 Moreta, Silvia
Delgado-Marin, Maria
Fernandez-Rodriguez, Blanca
Zaragoza, Carlos
Saura, Marta
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Facultad de Medicina
dc.subject.none.fl_str_mv aging
biomarkers
calcific aortic valve disease
cardiovascular disease
Calcific aortic valve disease
Aging
Biomarkers
Cardiovascular disease
General Medicine
Biochemistry
Clinical Biochemistry
SDG 3 - Good Health and Well-being
Journal Article
Review
yes
topic aging
biomarkers
calcific aortic valve disease
cardiovascular disease
Calcific aortic valve disease
Aging
Biomarkers
Cardiovascular disease
General Medicine
Biochemistry
Clinical Biochemistry
SDG 3 - Good Health and Well-being
Journal Article
Review
yes
description Background: Calcific aortic valve disease (CAVD) is the predominant valvular pathology in older adults, advancing from aortic sclerosis to life-threatening stenosis. Without effective medical therapies, intervention mainly relies on timely valve replacement, although silent myocardial and valvular damage may progress before symptoms arise. Early, non-invasive detection of disease activity is a crucial unmet need. Aims: To review circulating and mechanistic biomarkers reflecting the core pathogenic pathways of CAVD and asses their potential for early detection and patient-specific risk stratification. Methods: Narrative review of literature focusing on traditional protein biomarkers, emerging non-coding RNAs, and extracellular vesicles (EVs) associated with lipid oxidation and inflammation, bone and mineral metabolism, extracellular matrix (ECM) remodelling, endothelial dysfunction and non-coding RNA regulation. Results: Traditional protein biomarkers—such as lipoprotein(a), osteopontin, fetuin-A, galectin-3 and matrix metalloproteinases—offer insights into the disease and correlate with disease burden but lack sensitivity for detecting early-stage CAVD. Emerging non-coding RNA markers, including long non-coding RNAs (lncRNAs) and microRNAs (like miR-30b and miR-125b), show promise as predictive and diagnostic tools by mediating key molecular pathways involved in calcification and inflammation. EVs, which carry proteins, lipids and nucleic acids across all pathogenic pathways, provide stable and comprehensive signatures that enhance risk stratification compared to conventional markers. Notably, no single biomarker has demonstrated sufficient sensitivity or specificity across all stages of the disease. Combining proteins, RNAs and EV cargo into integrative, multimodal panels—supported by proteomics and transcriptomics—provides the greatest potential for early detection and patient-specific management. However, further validation in prospective cohorts and standardization of assays are necessary before clinical implementation. Conclusion: Biomarker-guided approaches could revolutionize CAVD management by enabling early detection and patient stratification before irreversible valvular damage occurs.
publishDate 2026
dc.date.none.fl_str_mv 2026
2026-01-01
2026
2026-01-01
dc.type.none.fl_str_mv review article
http://purl.org/coar/resource_type/c_dcae04bc
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10641/6717
url https://hdl.handle.net/10641/6717
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2

http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2

http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
instname:Universidad de Málaga
instname_str Universidad de Málaga
reponame_str DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
collection DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412354750414848
score 15.812429

Similares en LA Referencia